83 FR 62585 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 83, Issue 233 (December 4, 2018)
Food and Drug Administration
Federal Register Volume 83, Issue 233 (December 4, 2018)
| Page Range | 62585-62589 | |
| FR Document | 2018-26295 |
[Federal Register Volume 83, Number 233 (Tuesday, December 4, 2018)] [Notices] [Pages 62585-62589] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-26295] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2014-D-0609] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of [[Page 62586]] information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by January 3, 2019. ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to [email protected]. All comments should be identified with the OMB control number 0910-0806. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A- 12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794, [email protected]. SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Guidance for Industry: Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification OMB Control Number 0910-0806--Extension This information collection supports the previously captioned Agency guidance and associated Form FDA 3911. The Drug Supply Chain Security Act (DSCSA) (Title II of Pub. L. 113-54) added new section 582(h)(2) to the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360eee-1(h)(2)), requiring FDA to issue guidance to aid trading partners in identifying a suspect product and terminating a notification regarding an illegitimate product and, for a manufacturer, a product with a high risk of illegitimacy. Suspect product is defined in section 581(21) of the FD&C Act (21 U.S.C. 360eee(21)), as a product for which there is reason to believe it: (1) Is potentially counterfeit, diverted, or stolen; (2) is potentially intentionally adulterated such that the product would result in serious adverse health consequences or death to humans; (3) is potentially the subject of a fraudulent transaction; or (4) appears otherwise unfit for distribution such that the product would result in serious adverse health consequences or death to humans. Beginning January 1, 2015, section 582 of the FD&C Act requires certain trading partners, upon determining that a product in their possession or control is a suspect product, to quarantine the product while they promptly conduct an investigation to determine whether the product is an illegitimate product. Illegitimate product is defined in section 581(8) of the FD&C Act as a product for which credible evidence shows that it: (1) Is counterfeit, diverted, or stolen; (2) is intentionally adulterated such that the product would result in serious adverse health consequences or death to humans; (3) is the subject of a fraudulent transaction; or (4) appears otherwise unfit for distribution such that the product would be reasonably likely to result in serious adverse health consequences or death to humans. Also beginning January 1, 2015, trading partners must, upon determining that a product in their possession or control is illegitimate, notify FDA and all immediate trading partners that they have reason to believe they may have received the illegitimate product not later than 24 hours after making the determination. Under section 582(b)(4)(B)(ii)(II) of the FD&C Act, manufacturers are additionally required to notify FDA and any immediate trading partners that they believe may possess a product manufactured by or purportedly manufactured by the manufacturer not later than 24 hours after the determination is made or being notified by FDA or a trading partner that the product has a high risk of illegitimacy. Under section 202 of the DSCSA, manufacturers, repackagers, wholesale distributors, and dispensers (e.g., pharmacies) must: (1) Notify FDA when they have determined that a product in their possession or control is illegitimate (and, for manufacturers, when they have determined or been notified by FDA or a trading partner that a product has a high risk of illegitimacy); (2) notify certain immediate trading partners about an illegitimate product that they may have received (and, for manufacturers, that a product has a high risk of illegitimacy); (3) terminate notifications regarding illegitimate products (and, for manufacturers, a product with a high risk of illegitimacy), in consultation with FDA, when the notifications are no longer necessary; and (4) notify immediate trading partners when the notifications are terminated. Trading partners should use Form FDA 3911 to submit notifications and requests for terminations of notifications to FDA. Form FDA 3911 is available on FDA's web page (https://www.accessdata.fda.gov/scripts/cder/email/drugnotification.cfm). A. Notifications to FDA Under section 582(b)(4)(B)(ii)(I), (c)(4)(B)(ii), (d)(4)(B)(ii), and (e)(4)(B)(ii) of the FD&C Act, as amended by the DSCSA, and beginning not later than January 1, 2015, a manufacturer, repackager, wholesale distributor, or dispenser who determines that a product in its possession or control is illegitimate must notify FDA of that determination not later than 24 hours after the determination is made. In addition, section 582(b)(4)(B)(ii)(II) of the FD&C Act requires manufacturers to notify FDA when a manufacturer determines that a product poses a high risk of illegitimacy. We originally estimated that all manufacturers, repackagers, wholesale distributors, and dispensers would collectively submit 5,000 notifications per year. This estimate included the notifications by trading partners that have determined that illegitimate product is in their possession or control, as well as notifications by manufacturers that have determined a product poses a high risk of illegitimacy. As discussed in our Federal Register notice of June 11, 2014 (79 FR 33564), the estimate was based on our experience with field alert reports (Form FDA 3331) that holders of approved drug applications are required to submit for certain drug quality issues (21 CFR 314.81(b)(1)) and with reports of the falsification of drug sample records, diversion, loss, and known theft of prescription drug samples as currently required under Sec. 203.37 (21 CFR 203.37). Upon evaluation of the number of notifications we received for fiscal years 2016 and 2017, however, we are lowering our estimate to 150 notifications. We are also combining the estimates for manufacturers and repackagers because FDA's establishment and drug product listing database indicates that many companies perform activities of both manufacturers and repackagers. Although the DSCSA specifically defines dispensers, for estimation purposes, we are using estimates for pharmacies in general terms based on those that must comply with the new requirements under section 582(d) of the FD&C Act. Because manufacturers, repackagers, and wholesale distributors are collectively responsible for prescription drugs from the point of manufacturing through distribution in the drug supply chain, we assume that most notifications of illegitimate products are [[Page 62587]] submitted by these three trading partners. The total number of respondents is comprised of 80 percent manufacturers (120), 15 percent wholesale distributors (22), and 5 percent pharmacies (8). We estimate that the number of annual notifications will vary from 0 to 2 for manufacturers/repackagers, as well as from pharmacies, with the vast majority of companies making no notifications. Although FDA's establishment and drug product listing database currently contains registrations for approximately 6,500 manufacturers and repackagers, we estimate that approximately 120 manufacturers/repackagers will notify us of illegitimate products an average of one time per year. Although we estimate approximately 69,000 pharmacy sites in the United States, based on data from the National Association of Chain Drug Stores, the National Community Pharmacists Association, and the American Hospital Association, we estimate that approximately 8 pharmacies will notify FDA of illegitimate product an average of one time per year. According to the Healthcare Distribution Alliance (formerly known as Healthcare Distribution Management Association), approximately 30 wholesale distributors are responsible for over 90 percent of drug distributions; based on sales and because FDA is estimating that over 2,200 small wholesale distributors might be responsible for the remaining 10 percent of drug sales, we estimate that wholesale distributors will be responsible for making about an average of 1 notification per year to account for the estimated 22 notifications that FDA will receive regarding illegitimate product. Each notification should include information about the person or entity initiating the notification, the product determined to be illegitimate or having a high risk of illegitimacy, and a description of the circumstances surrounding the event that prompted the notification. We estimate that each notification will take about 1 hour, as reflected in table 1. B. Notifications to Trading Partners of an Illegitimate Product or Product With a High Risk of Illegitimacy Under section 582(b)(4)(B)(ii)(I), (c)(4)(B)(ii), (d)(4)(B)(ii), and (e)(4)(B)(ii) of the FD&C Act, a trading partner who determines that a product in its possession is illegitimate must also notify all immediate trading partners that they believe may have received such illegitimate product not later than 24 hours after the determination is made. In addition, under section 582(b)(4)(B)(ii)(II) of the FD&C Act, a manufacturer is required to notify all immediate trading partners that the manufacturer believes may possess a product manufactured by or purported to be manufactured by the manufacturer not later than 24 hours after the determination is made or being notified by FDA or a trading partner that the product has a high risk of illegitimacy. Because the extent of distribution of any illegitimate product is likely to vary from one situation to another, we assume a wide distribution of each illegitimate product. We estimate that, for each notification made by a manufacturer or repackager to FDA, approximately 30 trading partners (based on the number of distributors) will also be notified. This results in approximately 3,600 notifications annually to trading partners of manufacturers/repackagers. This estimate includes the notifications by manufacturers and repackagers who have determined that illegitimate product is in their possession or control, as well as notifications by manufacturers that have determined that a product poses a high risk of illegitimacy. We estimate that a large wholesale distributor may have up to 4,500 trading partners, but a small wholesale distributor may have 200 trading partners, for an average of approximately 2,350. We originally estimated that a wholesale distributor would notify all 2,350 trading partners for each of the illegitimate products identified. However, we are lowering our estimate as a result of our experience with the collection and informal feedback from industry to reflect that 22 respondents will make 1,175 disclosures for a total of 25,850 disclosures annually; and that each disclosure will require approximately 12 minutes, for a total of 5,170 hours annually. We estimate that a pharmacy purchases prescription drugs from an average of two wholesale distributors. Therefore, a pharmacy would notify 2 trading partners for each of the 8 illegitimate products identified, resulting in approximately 16 notifications annually to pharmacy trading partners. Manufacturers/repackagers, wholesale distributors, and pharmacies may notify their trading partners using existing systems and processes used for similar types of communications. Such communications may include, but are not limited to, posting notifications on a company website, sending an email, telephoning, or mailing or faxing a letter or notification. The information contained in the notification to the immediate trading partner should be the same as or based on the notification that was already submitted to FDA. We estimate that, for all trading partners, each notification of immediate trading partners will take approximately 0.2 hour (12 minutes). The estimated total burden hours that manufacturers/repackagers, wholesale distributors, and pharmacies will take to notify trading partners is approximately 5,893 hours annually, as reflected in table 2. C. Consultations With FDA and Termination of Notification Section 582(b)(4)(B)(iv), (c)(4)(B)(iv), (d)(4)(B)(iv), and (e)(4)(B)(iv) of the FD&C Act requires that a trading partner who determines, in consultation with FDA, that a notification made under section 582(b)(4)(B)(ii), (c)(4)(B)(ii), (d)(4)(B)(ii), or (e)(4)(B)(ii) is no longer necessary must terminate the notification. The guidance for industry sets forth the process by which trading partners should consult with FDA to terminate notifications that are no longer necessary. Each request for termination of notification must include information about the person or entity initiating the request for termination, the illegitimate product or product with a high risk of illegitimacy, the notification that was issued, and an explanation about what actions have taken place or what information has become available that make the notification no longer necessary. Trading partners should also include the FDA-assigned incident number associated with the initial notification on the request for termination. The request for a termination will be viewed as a request for consultation with FDA. We estimate that the same amount of time will be required to provide the information necessary to request termination as is required to make the notification. The time required to investigate and resolve an illegitimate product notification will vary, but we assume that each notification will eventually be terminated. We assume that the number of requests for termination of a notification per year will be the same as the original number of notifications for a given year. The estimated total burden hours of making requests for termination of notifications to FDA is 150 hours annually, as reflected in table 3. D. Notifications to Trading Partners That a Notification Has Been Terminated Section 582(b)(4)(B)(iv), (c)(4)(B)(iv), (d)(4)(B)(iv), and (e)(4)(B)(iv) of the [[Page 62588]] FD&C Act requires that a trading partner who, in consultation with FDA, terminates a notification made under section 582(b)(4)(B)(ii)(I) or (II), (c)(4)(B)(ii), (d)(4)(B)(ii), or (e)(4)(B)(ii) must also promptly inform previously-notified immediate trading partners that the notification has been terminated. We estimate that the burden for notifying trading partners of an illegitimate product and the number of trading partners notified will be the same as the estimates for notification of termination. The estimated total burden hours of notifying trading partners that the notification is terminated is approximately 5,893 hours annually, as reflected in table 4. In the Federal Register of September 6, 2018 (83 FR 45254), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received. FDA estimates the burden of this collection of information as follows: Table 1--Estimated Annual Reporting Burden--Notifications to FDA \1\ ---------------------------------------------------------------------------------------------------------------- Number of Respondent description Number of responses per Total annual Average burden Total hours respondents respondent responses per response ---------------------------------------------------------------------------------------------------------------- Manufacturers and Repackagers. 120 1 120 1............... 120 Wholesale Distributors........ 22 1 22 1............... 22 Dispensers.................... 8 1 8 1............... 8 --------------------------------------------------------------------------------- Total..................... .............. .............. .............. ................ 150 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 2--Estimated Annual Third-Party Disclosure Burden for Notifications to Trading Partners of an Illegitimate Product \1\ ---------------------------------------------------------------------------------------------------------------- Number of Respondent description Number of disclosures Total annual Average burden Total hours respondents per respondent disclosures per disclosure ---------------------------------------------------------------------------------------------------------------- Manufacturers and Repackagers. 120 30 3,600 0.20 (12 720 minutes). Wholesale Distributors........ 22 1,175 25,850 0.20 (12 5,170 minutes). Dispensers.................... 8 2 16 0.20 (12 3 minutes). --------------------------------------------------------------------------------- Total..................... .............. .............. .............. ................ 5,893 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 3--Estimated Annual Reporting Burden for Consultation With FDA and Termination of Notification \1\ ---------------------------------------------------------------------------------------------------------------- Number of Respondent description Number of responses per Total annual Average burden Total hours respondents respondent responses per response ---------------------------------------------------------------------------------------------------------------- Manufacturers and Repackagers. 120 1 120 1............... 120 Wholesale Distributors........ 22 1 22 1............... 22 Dispensers.................... 8 1 8 1............... 8 --------------------------------------------------------------------------------- Total..................... .............. .............. .............. ................ 150 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 4--Estimated Annual Third-Party Disclosure Burden for Notifications to Trading Partners of an Illegitimate Product Termination \1\ ---------------------------------------------------------------------------------------------------------------- Number of Respondent description Number of disclosures Total annual Average burden Total hours respondents per respondent disclosures per disclosure ---------------------------------------------------------------------------------------------------------------- Manufacturers and Repackagers. 120 30 3,600 0.2 (12 minutes) 720 Wholesale Distributors........ 22 1,175 25,850 0.2 (12 minutes) 5,170 Dispensers.................... 8 2 16 0.2 (12 minutes) 3 --------------------------------------------------------------------------------- Total..................... .............. .............. .............. ................ 5,893 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. [[Page 62589]] Cumulatively, the total estimated burden is 12,086 annual hours, which reflects a significant decrease. We base this adjustment on our experience with the information collection since its establishment and implementation. Dated: November 28, 2018. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2018-26295 Filed 12-3-18; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 83, No. 233 / Tuesday, December 4, 2018 / Notices 62585
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued
Annual
Number of Total annual Hours per
21 CFR section FDA form No. frequency Total hours
respondents responses response
per response
807.22(b)(2) 3—Other Updates of Reg-
istration ................................................. 3673 2,687 1 2,687 0.5 1,344
807.22(b)(3) 3—Annual Update of Listing
Information ............................................ 3673 22,607 1 22,607 0.5 11,304
807.26(e) 3—Labeling and Advertisement
Submitted at FDA Request .................. ........................ 71 1 71 1 71
807.34(a) 2—Initial Registration and List-
ing when Electronic Filing Waiver
Granted ................................................. ........................ 1 1 1 1 1
807.34(a) 3—Annual Registration and
Listing when Electronic Filing Waiver
Granted ................................................. ........................ 1 1 1 1 1
807.40(b)(2) 3—Annual Update of US
Agent Information ................................. 3673 1,615 1 1,615 0.5 808
807.40(b)(3) 3—US Agent Responses to
FDA Requests for Information ............. 3673 1,535 1 1,535 0.25 384
807.41(a) 3—Identification of Initial Im-
porters by Foreign Establishments ...... 3673 12,983 1 12,983 0.5 6,492
807.41(b) 3—Identification of Other Par-
ties that Facilitate Import by Foreign
Establishments ..................................... 3673 12,983 1 12,983 0.5 6,492
Total One Time Burden .................... ........................ ........................ ........................ ........................ ........................ 14,975
Total Recurring Burden ............. ........................ ........................ ........................ ........................ ........................ 39,173
1 Totals are rounded to the nearest whole number.
2 One-Time Burden—Firm only provides initially.
3 Recurring Burden—Firm is required to review annually.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
Annual
Number of Total annual Hours per
21 CFR section frequency per Total hours
respondents records record
recordkeeper
807.25(d) 2—List of Officers, Directors, and Partners ......... 22,338 1 22,338 .25 5,585
(15 minutes)
807.26 2—Labeling and Advertisements Available for Re-
view .................................................................................. 17,032 4 68,128 .5 34,064
(30 minutes)
Total .............................................................................. ........................ ........................ ........................ ........................ 39,649
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
2 Recurring burden—Firm is required to keep records.
The following adjustments and Annual Update of Listing Information’’ DEPARTMENT OF HEALTH AND
program changes resulted in a 5,672- (¥ 0.25 hours). Based on our review of HUMAN SERVICES
hour decrease to the overall total hour the program, we believe these changes
burden estimate for this information to the burden estimate will more Food and Drug Administration
collection request. accurately reflect the current [Docket No. FDA–2014–D–0609]
• We adjusted the number of preparation time for these ICs.
respondents based on updated Agency Information Collection
registration and listing data. Dated: November 28, 2018.
Activities; Submission for Office of
• In the reporting burden table, we Leslie Kux,
Management and Budget Review;
corrected the table footnotes to Associate Commissioner for Policy. Comment Request; Drug Supply Chain
accurately indicate whether the [FR Doc. 2018–26303 Filed 12–3–18; 8:45 am] Security Act Implementation:
information collection (IC) is a one-time BILLING CODE 4164–01–P Identification of Suspect Product and
or reoccurring burden. Notification
• We also adjusted some of the IC
descriptions in the table for increased AGENCY: Food and Drug Administration,
clarity. HHS.
• We updated our estimate of Hours ACTION: Notice.
per Response for ‘‘807.22(a) Initial
Registration and Listing’’ (+ 0.5 hours), SUMMARY: The Food and Drug
‘‘807.22(b)(1) Annual Registration’’ Administration (FDA) is announcing
(¥ 0.25 hours), and ‘‘807.22(b)(3) that a proposed collection of
VerDate Sep<11>2014 19:26 Dec 03, 2018 Jkt 247001 PO 00000 Frm 00026 Fmt 4703 Sfmt 4703 E:\FR\FM\04DEN1.SGM 04DEN1](https://thefederalregister.org/doc/83_FR_62818/page/1.svg)
![Federal Register / Vol. 83, No. 233 / Tuesday, December 4, 2018 / Notices 62589
Cumulatively, the total estimated comment will be made public, you are both copies to the Dockets Management
burden is 12,086 annual hours, which solely responsible for ensuring that your Staff. If you do not wish your name and
reflects a significant decrease. We base comment does not include any contact information to be made publicly
this adjustment on our experience with confidential information that you or a available, you can provide this
the information collection since its third party may not wish to be posted, information on the cover sheet and not
establishment and implementation. such as medical information, your or in the body of your comments and you
Dated: November 28, 2018. anyone else’s Social Security number, or must identify this information as
confidential business information, such ‘‘confidential.’’ Any information marked
Leslie Kux,
as a manufacturing process. Please note as ‘‘confidential’’ will not be disclosed
Associate Commissioner for Policy.
that if you include your name, contact except in accordance with 21 CFR 10.20
[FR Doc. 2018–26295 Filed 12–3–18; 8:45 am] information, or other information that and other applicable disclosure law. For
BILLING CODE 4164–01–P identifies you in the body of your more information about FDA’s posting
comments, that information will be of comments to public dockets, see 80
posted on https://www.regulations.gov. FR 56469, September 18, 2015, or access
DEPARTMENT OF HEALTH AND • If you want to submit a comment the information at: https://www.gpo.gov/
HUMAN SERVICES with confidential information that you fdsys/pkg/FR-2015-09-18/pdf/2015-
do not wish to be made available to the 23389.pdf.
Food and Drug Administration public, submit the comment as a Docket: For access to the docket to
[Docket No. FDA–2017–D–5928] written/paper submission and in the read background documents or the
manner detailed (see ‘‘Written/Paper electronic and written/paper comments
Post-Complete Response Letter Submissions’’ and ‘‘Instructions’’). received, go to https://
Meetings Between the Food and Drug www.regulations.gov and insert the
Administration and Abbreviated New Written/Paper Submissions
docket number, found in brackets in the
Drug Application Applicants Under Submit written/paper submissions as heading of this document, into the
Generic Drug User Fee Amendments; follows: ‘‘Search’’ box and follow the prompts
Guidance for Industry; Availability • Mail/Hand delivery/Courier (for and/or go to the Dockets Management
written/paper submissions): Dockets Staff, 5630 Fishers Lane, Rm. 1061,
AGENCY: Food and Drug Administration, Management Staff (HFA–305), Food and Rockville, MD 20852.
HHS. Drug Administration, 5630 Fishers You may submit comments on any
ACTION: Notice of availability. Lane, Rm. 1061, Rockville, MD 20852. guidance at any time (see 21 CFR
• For written/paper comments 10.115(g)(5)).
SUMMARY: The Food and Drug submitted to the Dockets Management Submit written requests for single
Administration (FDA or Agency) is Staff, FDA will post your comment, as copies of this guidance to the Division
announcing the availability of a final well as any attachments, except for of Drug Information, Center for Drug
guidance for industry entitled ‘‘Post- information submitted, marked and Evaluation and Research, Food and
Complete Response Letter Meetings identified, as confidential, if submitted Drug Administration, 10001 New
Between FDA and ANDA Applicants as detailed in ‘‘Instructions.’’ Hampshire Ave., Hillandale Building,
Under GDUFA.’’ This guidance is Instructions: All submissions received 4th Floor, Silver Spring, MD 20993–
intended to clarify the criteria for must include the Docket No. FDA– 0002. Send one self-addressed adhesive
granting post-complete response letter 2017–D–5928 for ‘‘Post-Complete label to assist that office in processing
(CRL) meeting requests and the scope of Response Letter Meetings Between FDA your requests. See the SUPPLEMENTARY
discussions for granted meeting and ANDA Applicants Under GDUFA.’’ INFORMATION section for electronic
requests. This guidance provides Received comments will be placed in access to the guidance document.
procedures that will promote well- the docket and, except for those FOR FURTHER INFORMATION CONTACT: Lisa
managed post-CRL meetings and help submitted as ‘‘Confidential Bercu, Center for Drug Evaluation and
ensure that such meetings are scheduled Submissions,’’ publicly viewable at Research, Food and Drug
and conducted in accordance with the https://www.regulations.gov or at the Administration, 10903 New Hampshire
commitments made by FDA in Dockets Management Staff between 9 Ave., Silver Spring, MD 20993–0002,
connection with the reauthorization of a.m. and 4 p.m., Monday through 240–402–6902.
the Generic Drug User Fee Amendments Friday. SUPPLEMENTARY INFORMATION:
for Fiscal Years 2018–2022 (GDUFA II). • Confidential Submissions—To
DATES: The announcement of the submit a comment with confidential I. Background
guidance is published in the Federal information that you do not wish to be FDA is announcing the availability of
Register on December 4, 2018. made publicly available, submit your a guidance for industry entitled ‘‘Post-
ADDRESSES: You may submit either comments only as a written/paper Complete Response Letter Meetings
electronic or written comments on submission. You should submit two Between FDA and ANDA Applicants
Agency guidances at any time as copies total. One copy will include the Under GDUFA.’’ GDUFA was
follows: information you claim to be confidential reauthorized (GDUFA II) on August 18,
with a heading or cover note that states 2017, in order to facilitate timely access
Electronic Submissions ‘‘THIS DOCUMENT CONTAINS to high quality, affordable generic
Submit electronic comments in the CONFIDENTIAL INFORMATION.’’ The medicines. In accordance with the
following way: Agency will review this copy, including GDUFA Reauthorization Performance
• Federal eRulemaking Portal: the claimed confidential information, in Goals and Program Enhancements Fiscal
https://www.regulations.gov. Follow the its consideration of comments. The Years 2018–2022 (GDUFA II Goals or
instructions for submitting comments. second copy, which will have the Commitment Letter) that accompanied
Comments submitted electronically, claimed confidential information the legislation, FDA committed to
including attachments, to https:// redacted/blacked out, will be available schedule and conduct 90 percent of
www.regulations.gov will be posted to for public viewing and posted on post-CRL meetings within prescribed
the docket unchanged. Because your https://www.regulations.gov. Submit time frames.
VerDate Sep<11>2014 17:36 Dec 03, 2018 Jkt 247001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\04DEN1.SGM 04DEN1](https://thefederalregister.org/doc/83_FR_62818/page/5.svg)
Document Created: 2018-12-04 00:42:07
Document Modified: 2018-12-04 00:42:07
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Fax written comments on the collection of information by January 3, 2019. | |
| Contact | JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A- 12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794, [email protected] | |
| FR Citation | 83 FR 62585 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR